NOVN — Novartis AG Balance Sheet
0.000.00%
- CH₣174.58bn
- CH₣189.47bn
- $51.72bn
- 97
- 32
- 85
- 87
Annual balance sheet for Novartis AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 11,293 | 28,113 | 18,726 | 14,073 | 13,351 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 10,036 | 9,621 | 9,894 | 9,376 | 9,539 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 29,673 | 45,718 | 36,910 | 30,481 | 29,704 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 13,939 | 13,106 | 12,195 | 10,924 | 10,873 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 127,778 | 131,795 | 117,453 | 99,945 | 102,246 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 33,059 | 30,208 | 28,656 | 26,390 | 28,692 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 71,180 | 64,140 | 58,111 | 53,278 | 58,200 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 56,598 | 67,655 | 59,342 | 46,667 | 44,046 |
Total Liabilities & Shareholders' Equity | 127,778 | 131,795 | 117,453 | 99,945 | 102,246 |
Total Common Shares Outstanding |